Why IMU is a multi multi bagger, page-18824

That was always the strategy, you wally.

They recruited people specific to that region because that's where they wanted to market the drug. That's also why they did not test the drug a
gainst Herceptin, because those countries didn't have and/or couldn't afford it.



It's the high proportion of people that don't know what they are talking about on this forum who were spouting misinformation. IMU sat at a $2b MC with people saying it was worth 10x that for a drug to be sold to an oncology market 1/10th of the size.

Heed my warning, the VAXINA results are also very average. Durable Response Rate of 7.7% so far and no efficacy in IV patients as single agent. In a phase 1 trial, Reolysin achieved a DRR of 21% without additional agents or radiotherapy. That's just one example that overshadows VAXINA.

Keen to see holders of this stock doing an analysis against TVEC and other competitive OVs.